Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran

  Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis

– No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the 2-year Phase 2b Open-Label Expansion (OLE) Study

– Favorable and durable improvements in atherogenic lipoproteins, including remnant cholesterol, non-HDL cholesterol, and ApoB, were observed, with a safety profile consistent with earlier trials

https://www.businesswire.com/news/home/20260328205340/en/Arrowhead-Pharmaceuticals-Presents-New-Long-Term-Efficacy-and-Safety-Data-for-Plozasiran-Across-a-Spectrum-of-Hypertriglyceridemia-at-the-American-College-of-Cardiologys-75th-Annual-Scientific-Session-and-Expo